Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6269584 | 0.81 | TSHR (0.32) | TSHR | |
| SCHEMBL6724769 | 0.80 | TSHR (0.35) | TSHR | |
| SCHEMBL530219 | 0.80 | TSHR (0.35) | TSHR | |
| SCHEMBL530220 | 0.78 | TSHR (0.33) | TSHR | |
| SCHEMBL22325533 | 0.78 | TSHR (0.52) | TSHR | |
| SCHEMBL530525 | 0.76 | LMNA (0.41) | TSHR | |
| SCHEMBL244781 | 0.76 | TSHR (0.32) | TSHR | |
| SCHEMBL6724775 | 0.74 | TSHR (0.31) | TSHR | |
| SCHEMBL4334239 | 0.74 | MGAM (0.35) | TSHR | |
| SCHEMBL11177532 | 0.72 | HCAR2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220381-A1 | DNA-ENCODED FUNCTIONALIZED APTAMERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2023-07-13 | — | — | US | disclosed |
| WO-2022000087-A1 | DNA-ENCODED FUNCTIONALIZED APTAMERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2022-01-06 | — | — | WO | disclosed |
| WO-2017205539-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170342077-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| EP-3008052-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201073-A9 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2014201073-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
| EP-0761672-B1 | Cephalosporins containing in position 7 a substituted benzyloxyimino radical, processes for their preparation and intermediates for their preparation, their use as medicaments | AVENTIS PHARMA SA (FR) | 2001-11-07 | — | — | EP | disclosed |
| US-5710147-A | ANTIBIOTICS | ROUSSEL UCLAF (FR) | 1998-01-20 | — | — | US | disclosed |
| EP-0761672-A1 | Cephalosporin containing in position 7 a substituted benzyloxyimino radical, processes for their preparation and intermediates for their preparation, their use as medicaments | ROUSSEL UCLAF (FR) | 1997-03-12 | — | — | EP | disclosed |
| EP-0693496-A1 | Novel cephalosporins having a substituted benzyloxyimino radical in position 7, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | TSHR 1201/4885 |
| US-20230220381-A1 | DNA-ENCODED FUNCTIONALIZED APTAMERS | AS3MT, DNMT1, POLM | TSHR 2530/4885 |
| US-20170342077-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | CSPP1, CBR3, NPY2R | TSHR 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.